Projected improvements in recurrence-free survival in early stages of colorectal cancer is the most important factor limiting drug treatment opportunities for advanced disease.According to analysis of Pharmacor Patient Flow Model Colorectal Cancer, the growth in drug treatment opportunities for advanced disease will be limited to 15% between 2009 and 2024.
“Drug treatment opportunities for advanced colorectal cancer will be limited because of a sustained decrease in the recurrence risk in early stages of the disease,” said Decision Resources Epidemiologist Donal Minihan, M.V.B., Ph.D. “Yet, aging population trends will be responsible for growth in the number of diagnosed incident cases of colorectal cancer in all major markets, resulting in a 27% growth in drug treatment opportunities for newly diagnosed cases of colorectal cancer.”
The findings are derived from Decision Resources’ Pharmacor Patient Flow Models which utilize Decision Resources proprietary suite of epidemiological models.
